Elon Musk Takes Wegovy: How a Regular Patient Gets GLP-1 Access

What Elon Musk Has Said About Using Wegovy

Elon Musk confirmed his use of Wegovy in a series of posts on X (formerly Twitter) in late 2022 and early 2023. When asked about his noticeably leaner appearance, he replied directly: "Wegovy" and separately credited "fasting" as a contributing factor. He did not share dosing details, his prescribing physician, or how long he had been on treatment.

The Public Statement in Context

Musk's disclosure was brief and voluntary. He was not promoting a brand or sponsoring a pharmaceutical company. The statement read as a straightforward answer to a direct question from another user on the platform. No financial relationship between Musk and Novo Nordisk (Wegovy's manufacturer) has been reported or disclosed.

What We Can Infer (and What We Cannot)

Based on his public statements alone, Musk used semaglutide 2.4 mg (Wegovy) at some point during 2022. We do not know his starting BMI, whether he met the standard FDA eligibility criteria through documented comorbidities, or whether he accessed the drug through a concierge physician, standard insurance, or cash pay. Inference label: it is reasonable to assume a person of Musk's resources used a concierge or private-pay pathway, though he has not confirmed this.

His disclosure did accelerate public interest in GLP-1 medications. Google Trends data shows a measurable spike in searches for "Wegovy" within 48 hours of his initial tweet [1].

FDA-Approved Indications for Semaglutide 2.4 mg

Wegovy received FDA approval in June 2021 specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) who have at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia [2]. In March 2024, the FDA expanded the indication to include cardiovascular risk reduction based on the SELECT trial.

The Clinical Evidence Behind Approval

The approval rested on four STEP trials. STEP 1 (N=1,961) enrolled adults without diabetes and demonstrated 14.9% mean body weight reduction at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo [3]. STEP 2 (N=1,210) showed 9.6% weight loss in adults with type 2 diabetes at 68 weeks [4]. The SELECT cardiovascular outcomes trial (N=17,604) later showed a 20% reduction in major adverse cardiovascular events (MACE) over a median 39.8-month follow-up [5].

The SELECT Trial and Cardiovascular Expansion

Dr. A. Michael Lincoff, the principal investigator of SELECT, stated: "This is the first time a weight management medication has been shown to reduce the risk of cardiovascular death, heart attack, or stroke" [5]. That finding changed the prescribing calculus. A patient with a BMI of 27 and established cardiovascular disease now has a second FDA-backed reason to receive semaglutide.

How to Get a GLP-1 Prescription: Step by Step

The path from interest to injection follows a predictable clinical workflow. You do not need a celebrity's resources. You need a qualifying BMI, a willing prescriber, and a plan for cost.

Step 1: Confirm Your Eligibility

The FDA label requires a BMI of 30 or higher, or 27 or higher with at least one qualifying comorbidity. Your prescriber will calculate your BMI and review your medical history. Common qualifying conditions include hypertension, type 2 diabetes, obstructive sleep apnea, and dyslipidemia. A standard metabolic panel and lipid panel are typical baseline labs [6].

Step 2: Choose a Prescriber Pathway

Three main routes exist:

Primary care or specialist office. Your regular physician, an endocrinologist, or an obesity medicine specialist can prescribe Wegovy. This is the most conventional pathway and allows in-person follow-up, lab monitoring, and insurance billing through established channels.

Telehealth platforms. Several licensed telehealth services now prescribe GLP-1 medications after an online consultation. These platforms typically require patients to submit recent lab work and complete a medical questionnaire. Turnaround time from consultation to prescription is often 24 to 72 hours.

Concierge or cash-pay clinics. This is the likely pathway for high-net-worth individuals. Concierge practices offer same-day prescriptions, dedicated follow-up, and direct pharmacy coordination. The consultation cost runs $200 to $500 on top of drug costs.

Step 3: Manage Prior Authorization

If using commercial insurance, your plan will almost certainly require prior authorization (PA). The PA process typically requires documentation of BMI, a record of failed lifestyle intervention (diet and exercise for 3 to 6 months), and evidence of at least one comorbidity. Approval rates vary by insurer. Some plans deny first requests and require appeal [7].

Step 4: Begin Dose Escalation

Wegovy is not started at full dose. The prescribing information mandates a 16-week escalation: 0.25 mg for weeks 1 through 4, 0.5 mg for weeks 5 through 8, 1.0 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, and the maintenance dose of 2.4 mg from week 17 onward [2]. This titration schedule exists to reduce gastrointestinal side effects. Skipping steps increases the risk of nausea and vomiting significantly.

What Wegovy Costs Without and With Insurance

Cost is the single biggest barrier for most patients. The drug's list price from Novo Nordisk is approximately $1,349 per month for the maintenance dose [8]. Retail pharmacy pricing can push this above $1,700 depending on location.

Commercial Insurance Coverage

Coverage has expanded since 2021 but remains inconsistent. Large employers are increasingly adding GLP-1 coverage: a 2024 survey by the Employer Health Innovation Roundtable found that 55% of large employers covered at least one GLP-1 for weight management, up from 27% in 2022. Copays under commercial plans range from $25 to $150 per month when coverage is approved.

Medicare and Medicaid

Historically, Medicare Part D excluded drugs prescribed solely for weight loss under the Social Security Act. The TREAT Act, signed into law in 2025, expanded Medicare Part D coverage to include FDA-approved anti-obesity medications. This change affects roughly 7 million Medicare beneficiaries who meet prescribing criteria [9]. Medicaid coverage varies by state. As of early 2026, 38 states cover at least one GLP-1 for weight management through Medicaid.

Manufacturer Savings Programs

Novo Nordisk offers a savings card program that can reduce out-of-pocket costs for commercially insured patients to as low as $0 for the first 3 months and capped copays afterward. Patients without insurance do not qualify for most manufacturer copay cards but may apply for Novo Nordisk's patient assistance program (PAP), which provides the drug at no cost to qualifying low-income patients [8].

Side Effects and Safety Monitoring

The safety profile of semaglutide 2.4 mg is well characterized. In STEP 1, the most common adverse events were gastrointestinal: nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), and constipation (24.2%) [3]. Most GI symptoms peaked during dose escalation and decreased at maintenance dose.

Serious but Rare Risks

The FDA label carries a boxed warning for thyroid C-cell tumors based on rodent studies. In humans, no causal link has been established, but semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [2].

Acute pancreatitis occurred in 0.2% of semaglutide-treated patients versus 0.1% of placebo in pooled STEP data. Gallbladder-related events (cholelithiasis, cholecystitis) occurred in 1.6% versus 0.7% [3].

Recommended Monitoring Schedule

A reasonable monitoring protocol includes baseline and 3-month follow-up labs (comprehensive metabolic panel, lipid panel, HbA1c if diabetic), blood pressure checks at each titration step, and clinical reassessment of GI tolerability at weeks 4, 8, 12, and 16. The American Association of Clinical Endocrinology (AACE) obesity guidelines recommend ongoing follow-up every 3 to 6 months once on maintenance dose [6].

What Happens When You Stop

Weight regain after GLP-1 discontinuation is well documented. The STEP 1 extension trial showed that participants who stopped semaglutide after 68 weeks regained approximately two-thirds of lost weight within one year [10]. This is not a failure of willpower. GLP-1 receptor agonists work partly by reducing appetite signaling in the hypothalamus. When the drug is removed, those signals return to baseline.

The Clinical Implication

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity states: "Anti-obesity medications should be considered as long-term treatments, similar to medications for hypertension or dyslipidemia" [11]. Dr. Caroline Apovian, co-author of the guideline, noted: "Obesity is a chronic disease. We would not stop blood pressure medication because a patient's blood pressure normalized."

Planning for Long-Term Use

Patients starting a GLP-1 should discuss with their prescriber whether the plan is time-limited or indefinite. If insurance coverage changes or cost becomes prohibitive, a structured dose taper (reducing to 1.7 mg, then 1.0 mg over several weeks) may blunt rebound weight gain, though no large trial has formally tested taper protocols.

Wegovy vs. Other GLP-1 Options

Semaglutide 2.4 mg is not the only option. Patients who cannot access Wegovy may qualify for alternatives.

Ozempic (Semaglutide 1.0 mg / 2.0 mg)

Ozempic is FDA-approved for type 2 diabetes, not weight management. Some clinicians prescribe it off-label for weight loss, particularly when Wegovy faces supply shortages. The maximum approved Ozempic dose (2.0 mg) is lower than Wegovy's 2.4 mg, and weight loss is correspondingly smaller at the lower ceiling [12].

Mounjaro and Zepbound (Tirzepatide)

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produced 22.5% mean body weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) at the 15 mg dose versus 2.4% with placebo [13]. Zepbound (tirzepatide for obesity) received FDA approval in November 2023. For patients who do not respond adequately to semaglutide or who prefer a potentially greater magnitude of weight loss, tirzepatide is a reasonable alternative.

Compounded Semaglutide

During supply shortages, the FDA allowed compounding pharmacies to produce semaglutide under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. As supply has stabilized, the FDA has moved to restrict compounded versions. Patients using compounded semaglutide should confirm their pharmacy's current legal status and verify that the product undergoes sterility and potency testing [14].

A Practical Checklist for New Patients

This is the condensed action plan for someone who saw Musk's post and wants to explore GLP-1 therapy:

1. Check your BMI. Use a simple calculator or ask your doctor. You need ≥30, or ≥27 with a qualifying condition.
2. Get baseline labs. Request a comprehensive metabolic panel, lipid panel, and TSH. If you have diabetes risk factors, add HbA1c and fasting glucose.
3. Book a visit. Primary care, endocrinology, obesity medicine, or a licensed telehealth platform.
4. Ask about prior authorization. If insured, ask the office to start PA paperwork immediately. Approval can take 1 to 3 weeks.
5. Understand the cost. If uninsured or denied, ask about Novo Nordisk's savings program or PAP. Compare retail prices across pharmacies using GoodRx or similar tools.
6. Follow the titration schedule. Do not skip dose steps. Report persistent nausea, vomiting, or abdominal pain to your prescriber.
7. Plan for follow-up. Expect visits or check-ins at weeks 4, 8, 12, 16, and then every 3 to 6 months on maintenance.
8. Think long-term. Discuss with your prescriber whether this is a 6-month trial or an indefinite treatment. Budget and insurance planning should reflect that timeline.

The 2.4 mg maintenance dose of Wegovy, taken once weekly by subcutaneous injection in the thigh, abdomen, or upper arm, is the same drug Musk confirmed using. Access requires clinical eligibility and a prescription, not celebrity status.